Learn about the potential side effects of iron protein succinylate. Includes common and rare side effects information for consumers and healthcare professionals. Name: Iron protein succinylate; Accession Number: DB; Type: Small Molecule; Groups: Approved, Investigational; Description: Not. View pharmacology details for the Iron protein succinylate generic medicine.
|Published (Last):||23 January 2010|
|PDF File Size:||7.68 Mb|
|ePub File Size:||5.13 Mb|
|Price:||Free* [*Free Regsitration Required]|
To evaluate the efficacy and safety of iron protein succinylate IPS oral solution in preventing and treating anemia of prematurity AOP.
Treatment began at two weeks after birth. A systematic review was conducted to analyze the tolerability of several oral iron supplements based on data obtained in available publications and to report the incidence of adverse effects AEs for each supplement both overall and gastrointestinal. Electronic databases – Medline, the Cochrane Library, and Embase were searched for studies published up to January Clinical or observational studies reporting data on the tolerability of oral iron supplements were included.
What Is Known And Objective: Toxic Epidermal Necrolysis Syndrome falls in the spectrum of acute idiosyncratic bullous disorders with medications being the major aetiological factor. The authors review the relevant literature and report a case of Toxic Epidermal Necrolysis Syndrome where two medications, iron protein succinylate and dabigatran, not previously associated with the disorder might have acted as precipitants to it.
An year-old female recently introduced to iron protein succinylate and dabigatran, presented with a widespread rash consisting of erythematous macules symmetrically distributed on her torso and both upper and lower limbs, down to her extremities. The criteria for the diagnosis of anemia were Hb Read More.
Seventy-six patients with Hb levels Read More. Iron therapy is necessary in a wide variety of clinical situations, and new formulations with improved tolerability and efficacy would be a welcome alternative to ferrous sulfate.
A trivalent iron protein complex has been developed using an N-acetyl-aspartylated derivative of casein Fe-ASP for oral iron therapy. This paper provides an overview of the pharmacokinetic and clinical data on Fe-ASP use.
A child allergic to cow’s milk developed a mild systemic allergic reaction after the first dose of Ferplex 40 iron proteinsuccinylate. Skin tests and in vitro studies were performed in the child, in three cow’s milk-allergic controls and in a non-allergic control. The aim of this study was to evaluate the efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy.
One hundred and thirty anemic pregnant women were studied. Inclusion criteria were iron-deficiency type of anemia, and hemoglobin levels below of The most significant adverse effect of repeated oral administration of iron-containing antianaemic preparations is the gastroduodenal toxicity, attributable to a direct toxic effect of iron on the glandular epithelium.
To assess gastroduodenal mucosal damage and the potential protective effect of different antianaemic preparations, a study was carried out to compare the gastroduodenal toxicity caused by three different types of antianaemic drugs in normal and anaemic rats administered at repeated therapeutic doses. Histological damage to the gastroduodenal mucosa was evaluated using light and electron microscopy.
To evaluate whether folate supplementation to iron is able to accelerate solving of iron deficiency anaemia in pregnancy. Multicentre, double blind, randomised clinical trial. Nine hospital gynaecologic units located in Mexico. Assay samples were treated with 0. Iron protein succinylate is a non-toxic therapeutic iron compound.
We set out to characterise the structure of this compound and investigate the importance of digestion and intestinal reduction in determining absorption of the compound. Iron proteinsuccinylate ITFCAS is an iron derivative for the oral treatment of iron deficiency anemia. Its efficacy and tolerability have been proved in about patients, enrolled in 3 multicenter clinical trials.
The first aim of this meta-analysis is to verify the increase of hemoglobin Hb in these patients treated with ITF, treated with iron sulphate and treated with iron-polysterene sulphonate. Severe iron deficiency in rats was found to be associated with abnormal lipid accumulation in the liver and impairment of the oxidative metabolism in the hepatic tissue.
This treatment fully reverted severe anemia associated with iron deficiency. A prospective, open, multicenter clinical trial was set up to evaluate the potential interaction of ITF with H2-receptor antagonists in patients affected with iron deficiency. Patients treated with H2 blockers and affected with iron deficiency or iron deficient anemia were given one tablet of ITF 60 mg iron twice daily for 60 days.
A second group of iron deficient patients with no anti H2 concurrent treatment were admitted to the same iron treatment, lasting 60 days. A total of children up to the age of 14 years were treated for iron deficiency or overt anemia. ITF was prescribed to children, and a commercially available ferrous polystyrene sulphonate preparation toin a randomized double-blind, double-dummy, ten-center trial.
One oral vial of ITF 60 mg iron was administered once a day to children weighing up to 40 kg; and twice a day to children with body weight equal or superior to 40 kg.
A prospective, controlled, double-blind, double-dummy, multicenter clinical trial was made to assess the efficacy and tolerability of iron-protein-succinylate ITF in comparison with a well known iron preparation in the treatment of iron deficiency or iron deficient anemia. Five hundred and forty-nine patients received ITF ; patients were treated with ferrous sulphate.
In this brief review the preclinical safety studies on iron protein succinylate synonym: ITF are presented. Iron protein succinylate is an iron-protein complex, in which iron is present in ferric form. It has been developed for oral iron-supplementation therapy and is characterized by a very favorable tolerability profile.
The main property of the derivative is to keep iron bonded at acidic pH values. This accounts for a better tolerability of the compound compared with iron salts, during the treatment of iron deficiency. The absorption of iron from iron succinyl-protein complexes was investigated in mice. Studying the gastrointestinal motor effects of iron compounds may help to elucidate the mechanism originating the gastrointestinal side effects of frequently reported during martial therapy.
The aims of the present study were: In 6 fasting, conscious dogs, fitted with 8 bipolar electrodes and 3 strain-gauge force transducers along the gastrointestinal tract, gastrointestinal motor activity was recorded.
Aim of this multicentric clinical trial was to evaluate the efficacy and tolerability of a new iron compound: Iron proteein induced a statistically significant improvement p less than 0. The absorption of iron after oral administration of 80 mg iron–protein–succinylate complex was evaluated by lrotein serum iron concentrations in 10 patients who had undergone total gastrectomy more than 1 year before and were suffering from hypochromic anaemia.
Serum iron concentrations in these patients were no different from those obtained in 10 ‘normal’ hypochromic anaemic patients. The effects of iron protein succinylate ITFan iron complex insoluble under acid conditions, and ferrous sulfate were studied in the rat. Iron absorption and kinetics were evaluated by measuring serum iron after oral administration of equidoses of iron to the anaemic rat.
The efficacy of simethicone available in liquid form as Mylicon Drops in the treatment of infant colic was assessed in 51 healthy infants between 2 and 12 weeks of age. The succiinylate trial consisted of a one-week study period.
iron protein succinylate Publications | PubFacts
Care-givers were to report on the infant’s response to treatment after one day and one week of treatment, and in terms of the overall quality of life of both infant and family. Serum iron curves were determined in two groups of iron deficient patients after oral administration of iron protein succinylate or ferritin. The increase induced by iron protein succinylate was more irron than that of ferritin. Iron protein succinylate is a new iron preparation for oral administration.
Iron protein succinylate Pharmacology & Usage Details | Medicine India
In a controlled study versus iron sulphate in 40 blood donors with low levels of stored iron, treatment for 30 days with iron protein succinylate resulted in greater iron absorption compared to the reference drug. Serum iron concentration significantly increased compared with baseline values only in patients given iron protein succinylate.
ITF, a soluble iron succinyl-protein complex, orally administered to the rat elevates the concentration of iron in the serum to a greater extent than ferritin.
The serum iron increase induced by ITF is delayed when compared with ferrous sulphate. The ITF absorption process, like that of ferritin, proceeds along the physiological pathways without bypassing the transfer succinylat of the intestinal mucosal cells since no further increase of serum metal is observed when giving high doses of ITF to the rat pretreated with a saturating dose of ferrous sulphate.
A product containing a high amount of iron and maintaining all the necessary characteristics of stability and solubility for a drug can be prepared by succinylating the proteins, in the specific case the milk proteins, before the reaction with the iron salt. For these derivatives a particular advantage can be achieved, the iron succinyl protein precipitates at the pH of the stomach further keeping the iron bonded and it re-solubilizes at pH higher than 7, the intestine pH level.
Electrophoresis indicates that the iron succinyl protein is homogeneous and gel filtration shows an apparent high molecular weight that contributes to the stability of the complexed iron. Sign In Join Now. Allergy and Immunology Obstetrics and Gynecology Physical Medicine and Rehabilitation Page 1 of 1. Yan Xing Xiao-Mei Succonylate. Read More View Article. Tolerability of different oral iron supplements: Curr Med Res Opin Apr 6;29 4: Epub Feb 6.
Iron Protein Succinylate
Iron complex, dabigatran and toxic epidermal necrolysis syndrome: J Clin Pharm Ther Apr 12;38 2: Epub Dec Total infusion of low molecular weight iron-dextran for treating postpartum anemia.
Clin Exp Obstet Gynecol ;38 2: Portein and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: Succinlate Haematol 31; 1: Epub Mar Overview of clinical trials in the treatment of iron deficiency with iron-acetyl-aspartylated casein. Flavio Lazzari Maria Carrara. Clin Drug Investig ;25 Acute allergic reaction to an iron compound in a milk-allergic patient. Pediatr Allergy Immunol May;17 3: The efficacy and tolerability of iron protein succinylate in the treatment of iron-deficiency anemia in pregnancy.
Clin Exp Obstet Gynecol ;32 2: A comparative study on the gastroduodenal progein of different antianaemic preparations. Hum Exp Toxicol Mar;22 3: An Med Interna Dec;19